Used in pharmaceutical synthesis as a key intermediate for kinase inhibitors, particularly in the development of targeted cancer therapies. Its boron-containing group enables Suzuki-Miyaura cross-coupling reactions, allowing efficient construction of biaryl structures common in drug molecules. The cyclopropylamino and sulfonamide moieties contribute to target binding selectivity and metabolic stability. Commonly employed in research settings for generating novel analogs in oncology and inflammation drug discovery programs.